Preclinical Development

Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG

Jason R. Hasenstein1, Ho-Chul Shin2, Kelsey Kasmerchak1, Darya Buehler3, Glen S. Kwon2, and Kevin R. Kozak1

Abstract

Triolimus is a first-in-class, multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-AAG. In this study, we examine the antitumor mechanisms of action, efficacy, and toxicity of Triolimus in vitro and in vivo. In vitro cytotoxicity testing of Triolimus was conducted using two aggressive adenocarcinomas including the lung cancer cell line, A549, and breast cancer cell line, MDA-MB-231. The three-drug combination of paclitaxel, rapamycin, and 17-AAG displayed potent cytotoxic synergy in both A549 and MDA-MB-231 cell lines. Mechanistically, the drug combination inhibited both the Ras/Raf/mitogen-activated protein kinase and PI3K/Akt/mTOR pathways. Triolimus was advanced into tumor xenograft models for assessment of efficacy, toxicity, and mechanisms of action. In vivo, a three-infusion schedule of Triolimus inhibited A549 and MDA-MB-231 tumor growth far more potently than paclitaxel-containing micelles and effected tumor cures in MDA-MB-231 tumor-bearing animals. Tumor growth delays resulted from a doubling in tumor cell apoptosis and a 50% reduction in tumor cell proliferation compared with paclitaxel-containing micelles. Enhanced antitumor efficacy was achieved without clinically significant increases in acute toxicity. Thus, Triolimus displays potent synergistic activity in vitro and antitumor activity in vivo with comparable toxicity to paclitaxel. These observations provide strong support for further development of Triolimus and an important proof of concept for safe, effective nanoparticle-based delivery of three complementary anticancer agents. Mol Cancer Ther; 11(10); 1–10. ©2012 AACR.

Introduction

A growing appreciation of the complexity and heterogeneity of cancer cells has led to interest in combination therapies that simultaneously target multiple key pathways in carcinogenesis and tumor progression (1). Complementing this is a growing recognition that cancer cells possess a broad-ranging capacity to activate compensatory signaling pathways to overcome barriers presented by single agent therapy. To facilitate simultaneous, rational molecular multitargeting, we used a nontoxic, micellar nanocarrier capable of efficiently solubilizing multiple drugs at concentrations expected to have activity in vivo (2–4). For preclinical testing, a priori selection of drugs in multidrug-loaded micelles was based on known independent activity, clinical relevance, and anticipated mechanisms of resistance. Paclitaxel is a cornerstone in the systemic management of an array of solid tumors including, notably, breast and lung cancer. Rapamycin has been reported to increase and prolong sensitivity to microtubule directed chemotherapeutic agents (5, 6) and may exert independent activity in some settings (7). Finally, the prototypical Hsp90 inhibitor, 17-AAG, was selected for micelle inclusion because of its independent activity in several settings and documented capacity to target compensatory pathways activated by mTOR inhibition, including Akt activation (8–11). The resultant 3-drug–loaded micelle was designated Triolimus (Fig. 1).

To assess the utility of Triolimus, we conducted formal combination index (i.e., synergy; CI) analyses and mechanistic studies of these drugs, alone and in combination, in vitro as well as efficacy, toxicity, and mechanistic studies in vivo.

Materials and Methods

Cell lines and pharmacologic agents

A549 and MDA-MB-231 cells were obtained from American Type Culture Collection (ATCC) and passaged for fewer than 6 months after resuscitation. ATCC cell line authentication includes short tandem repeat profiling, morphology monitoring, cytochrome C oxidase I testing and karyotyping. A549 cells were cultured in RPMI containing 5% heat inactivated fetal bovine serum and 1% penicillin/streptomycin. MDA-MB-231 cells were cultured in DMEM containing 5% FBS and 1% penicillin/
streptomycin. Paclitaxel, rapamycin, and 17-AAG were obtained from LC Laboratories. Drug-loaded poly(ethylene glycol)-block-poly(lactic-acid; PEG-PLA) micelles were prepared and characterized as previously described (12,13). Briefly, PEG-PLA, paclitaxel, 17-AAG, and rapamycin are dissolved in acetonitrile in a round-bottom flask. Acetonitrile is removed under reduced pressure and the resultant polymer film is rehydrated with double-distilled water. The aqueous solution is then centrifuged and filtered (0.45 μm). Before use, drug loading is quantified by reverse phase high-performance liquid chromatography. The drug ratio in Triolumus (paclitaxel:rapamycin:17-AAG, 2:1:2 by mass or 2:1:3 on a molar basis) was selected to permit mouse dosing of paclitaxel: rapamycin:17-AAG at 60 mg/kg:30 mg/kg: 60 mg/kg as previously reported (12).

**Immunoblotting and immunohistochemistry**

A549 and MDA-MB-231 cells were grown to approximately 70% confluence. Cells were then treated with dimethyl sulfoxide vehicle control, paclitaxel (30 nmol/L), rapamycin (30 nmol/L), 17-AAG (30 nmol/L), or combinations for 24 hours. The final concentration of DMSO was 0.1%. Cells were washed twice in cold PBS and protein isolated in cold NP-40 lysis buffer [50 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 1% NP-40, 0.5% deoxycholic acid, 10% glycerol, 2.5 mmol/L EGTA, 1 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L PMSF, 1 mmol/L Na3VO4, 20 mmol/L BGP, and 10 mg/mL of leupeptin and apro tinin]. Proteins were quantified using a standard Bradford absorbance assay. Proteins were separated on 4% to 20% gradient SDS-PAGE gels and transferred to polyvinylidene difluoride membrane by electrophoretic transfer. Membranes were subsequently blocked in 5% non-fat milk in Tris buffered saline-Tween buffer (TBST) [1 mmol Tris Base (pH 8.0), 150 mmol NaCl, 0.5% Tween-20] or 5% bovine serum albumin in TBST buffer. All primary antibodies for Western blot detection were from Cell Signaling Technology Inc. unless otherwise stated. Primary antibodies for Western blot detection of Akt (1:1000, Santa Cruz Biotechnology Inc.), phospho-Akt (1:1000), ERK 1/2 (1:1000), phospho-ERK 1/2 (1:1000), eIF4E (1:1000), phospho-eIF4E (1:1000), 4E-BP1 (1:1000), phospho-4E-BP1 (1:1000), p70S6K (1:1000), and phospho-p70S6K (1:1000) were applied overnight at 4°C. Secondary antibody for detection was either goat anti-rabbit IgG-HRP (1:4000, Santa Cruz Biotechnology Inc.) or goat anti-mouse IgG-HRP (1:4000, Santa Cruz Biotechnology Inc.). Proteins were detected via enhanced chemiluminescence detection system (Amersham Biosciences).

For Ki-67 and cleaved caspase-3 immunohistochemistry, tissue was fixed for 24 hours in 10% neutral buffered formalin, dehydrated through graded ethyl alcohols, paraffin infiltrated and embedded. Tissue sections were cut at 5 μm and mounted on glass slides. Slides were deparaffinized in xylene and hydrated through graded ethyl alcohols to water. Slides were washed with PBS 3 times. Nonspecific binding was blocked with 10% goat serum in PBS for 1 hour and endogenous peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 10 minutes. Endogenous biotin was blocked with 0.001% avidin in PBS for 10 minutes and the avidin quenched with 0.001% biotin in PBS for 10 minutes. The slides were then incubated with either anti-Ki-67 (US Biological) at a 1:800 dilution in PBS with 1% goat serum for 1 hour and endogenous peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 10 minutes. Endogenous biotin was blocked with 0.001% avidin in PBS for 10 minutes and the avidin quenched with 0.001% biotin in PBS for 10 minutes. The slides were then incubated with biotinylated goat anti-rabbit IgG (Vector Laboratories) at 1:200 in PBS for 1 hour at room temperature. Slides were washed in PBS and then incubated 30 minutes at room temperature with Vectastain ABC Elite (Vector...
Laboratories). Following PBS wash, slides were developed with DAB (Vector Laboratories) and counterstained with Mayer’s hematoxylin. All reagents and chemicals were from Sigma unless otherwise noted.

**Proliferation assays**

A549 and MDA-MB-231 cells were plated at 1,500 cells per well in 96-well plates and allowed to adhere overnight. Medium was aspirated and replaced with fresh media containing DMSO control, paclitaxel, rapamycin, 17-AAG, or drug combinations at 0 to 10,000 nmol/L. Final DMSO concentration was 0.1%. Cells were allowed to grow for 72 hours and cell proliferation was quantified using the WST-1 cell proliferation reagent (Roche Applied Science) according to manufacturer’s instructions. Dose-effect analyses were conducted using CompuSyn (CompuSyn, Inc).

**In vivo tumor control studies**

Athymic nude mice (6–8-week-old females) were obtained from Harlan Laboratories (Madison, WI). The care and treatment of experimental animals was in accordance with institutional guidelines. A549 cells (2 × 10⁶) were implanted subcutaneously in the flank. MDA-MB-231 cells (2 × 10⁶) were implanted in the mammary fat pad. For tumor growth delay studies, treatment was started when tumor volume reached approximately 200 mm³ for A549 tumors or when tumors were clearly palpable for MDA-MB-231 tumors. Following randomization, tumor-bearing animals were treated with micelles alone, paclitaxel-containing micelles (60 mg/kg) or Triolimus (17-AAG 60 mg/kg, paclitaxel 60 mg/kg, rapamycin 30 mg/kg) on days 0, 4, and 8 by tail vein injection. In the A549 model, an additional group was treated with isotonic saline. Tumor volume was determined by caliper measurement and calculated by the formula, volume = 0.5(large diameter) (small diameter)³.

**In vivo toxicity and mechanistic studies**

A549 tumor bearing animals (200 mm³) were treated with micelles alone, paclitaxel-containing micelles (60 mg/kg) or Triolimus (17-AAG 60 mg/kg, paclitaxel 60 mg/kg, rapamycin 30 mg/kg) on days 0, 4, and 8 by tail vein injection. At day 11, animals were sacrificed and whole blood and serum were collected. Normal tissues (lung, liver, kidney, and heart) and tumor were dissected and formalin-fixed. Complete blood counts and comprehensive metabolic panels were conducted by the Clinical Pathology Laboratory of the University of Wisconsin School of Veterinary Medicine, Madison, WI. Normal and tumor tissues were sectioned, hematoxylin and eosin stained and examined by a pathologist blinded to treatment group. Tumor tissues were additionally stained for Ki-67 and cleaved caspase-3 as described above. Ki-67- and cleaved caspase-3-positive cells were counted by an observer blinded to treatment group. Total cell number was quantified using Image J (National Institutes of Health).

**Statistical analyses**

Data are presented as means ± SE. Multigroup comparisons were conducted by ANOVA. When appropriate, Tukey’s honestly significant difference (HSD) test was applied to account for multiple comparisons. For two group comparisons, Student t test was used.

**Results**

**Paclitaxel, rapamycin, and 17-AAG display independent and synergistic cytotoxicity in vitro**

Paclitaxel, rapamycin, and 17-AAG exerted independent cytotoxic effects in vitro in A549 and MDA-MB-231 cells with IC₅₀ values ranging from the midnanomolar range to the low-micromolar range (Table 1). MDA-MB-231 cells were more resistant to rapamycin and 17-AAG compared with A549 cells. In both cell lines, the 3-drug combination displayed statistically significant, potent synergy whereas the effects of 2-drug combinations were more varied. The 2-drug combination of paclitaxel and 17-AAG displayed antagonism in A549 cells (CI > 1) but was modestly synergistic in MDA-MB-231 cells (CI < 1). Other 2-drug combinations displayed synergistic cytotoxicity in both cell lines. The 3-drug combination, either in an equimolar ratio or in the molar ratio in Triolimus (paclitaxel:rapamycin:17-AAG = 2:1:3), displayed combination indices less than 1 throughout the fractional affect range indicating this combination exerts synergistic cytotoxicity over a broad range of cell kill. Triolimus displayed the greatest synergy compared with other tested 2- and 3-drug combinations.

**Mechanisms of synergistic toxicity**

To identify potential mechanisms of synergistic cytotoxicity, A549 and MDA-MB-231 cells were treated with DMSO vehicle control (leftmost column), individual drugs, or combinations. Expression and activation of key molecular targets in PI3K/Akt/mTOR and Ras/Raf/mitogen-activated protein kinase (MAPK) pathways were determined by Western blotting. In A549 cells, rapamycin monotherapy resulted in the expected inhibition of p70S6K phosphorylation (Fig. 2A). Moreover, rapamycin monotherapy induced Akt activation. Inclusion of either paclitaxel or 17-AAG with rapamycin resulted in no change in mTOR inhibition as evidenced by persistent blockade of p70S6K phosphorylation. However, the addition of either paclitaxel or 17-AAG blocked compensatory Akt phosphorylation observed with rapamycin monotherapy. Paclitaxel, and all combination therapies, blocked basal ERK 1/2 activation whereas rapamycin and 17-AAG monotherapies did not. No Akt, p70S6K, 4E-BP1, ERK 1/2, or eIF4E activation was observed in cells treated with the 3-drug combination. Responses to drug treatment differed in MDA-MB-231 cells (Fig. 2B). Although rapamycin similarly inhibited p70S6K phosphorylation, compensatory Akt phosphorylation was not observed. Moreover, paclitaxel monotherapy appeared to modestly increase, rather than potently inhibit, ERK 1/2 phosphorylation. As in the case of A549 cells, MDA-MB-231 cells
Molecular Cancer Therapeutics

Mol Cancer Ther; 11(10) October 2012

Triolimus displays comparable toxicity to paclitaxel-containing micelles in vivo

In A549 tumor bearing mice, statistically significant treatment effects were evident by day 9 and persisted throughout the course of the experiment (Fig. 3A, ANOVA $P < 0.05$). Micelle alone treatment resulted in tumor growth indistinguishable from saline control. Paclitaxel-containing micelles had only modest effects on tumor growth with a statistically nonsignificant trend toward tumor growth delay evident late in the experimental course (Tukey’s HSD test, $P > 0.05$ at all time points). In contrast, Triolimus displayed potent and durable tumor control that differed significantly from saline control treatment from day 9 onward (Tukey’s HSD test, $P < 0.05$ at all time points).

In MDA-MB-231 tumor bearing mice, statistically significant treatment effects were evident by day 15 (Fig. 3B, ANOVA $P < 0.05$). Despite tumor delays with paclitaxel containing micelles, durable tumor control was not observed; all paclitaxel treated animals experienced persistent tumor regrowth by day 33. In contrast, Triolimus displayed much greater potency with durable tumor control. In fact, only 1 Triolimus treated animal eventually recurred with persistent tumor regrowth first evident at day 45. The remaining Triolimus treated animals were tumor-free more than 1 year following treatment initiation.

Table 1. Drug combination effects: combination index analysis of paclitaxel, rapamycin, and 17-AAG ($N = 4–5$ per condition)

<table>
<thead>
<tr>
<th></th>
<th>IC$_{50}$ nmol/L</th>
<th>CI at F$_{a10}$</th>
<th>CI at F$_{a25}$</th>
<th>CI at F$_{a50}$</th>
<th>CI at F$_{a75}$</th>
<th>CI at F$_{a90}$</th>
<th>Molar ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>100 ± 50</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Rapamycin</td>
<td>50 ± 6</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>17-AAG</td>
<td>380 ± 100</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Paclitaxel:rapamycin</td>
<td>23 ± 1</td>
<td>0.5 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>1:1</td>
</tr>
<tr>
<td>Paclitaxel:17-AAG</td>
<td>260 ± 70</td>
<td>2.5 ± 0.8</td>
<td>2.2 ± 0.7</td>
<td>2.0 ± 0.6</td>
<td>1.8 ± 0.5</td>
<td>1.6 ± 0.4</td>
<td>1:1</td>
</tr>
<tr>
<td>Rapamycin:17-AAG</td>
<td>36 ± 2</td>
<td>0.5 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>1:1</td>
</tr>
<tr>
<td>Paclitaxel:rapamycin:17-AAG</td>
<td>29 ± 2</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>1:1:1</td>
</tr>
<tr>
<td>Paclitaxel:rapamycin:17-AAG</td>
<td>27 ± 2</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>2:1:3</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>120 ± 20</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Rapamycin</td>
<td>440 ± 100</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>17-AAG</td>
<td>4,200 ± 1,300</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Paclitaxel:rapamycin</td>
<td>100 ± 10</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>1:1</td>
</tr>
<tr>
<td>Paclitaxel:17-AAG</td>
<td>140 ± 10</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>1:1</td>
</tr>
<tr>
<td>Rapamycin:17-AAG</td>
<td>380 ± 40</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>1:1</td>
</tr>
<tr>
<td>Paclitaxel:rapamycin:17-AAG</td>
<td>110 ± 10</td>
<td>0.5 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>1:1:1</td>
</tr>
<tr>
<td>Paclitaxel:rapamycin:17-AAG</td>
<td>110 ± 10</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>0.4 ± 0.1</td>
<td>2:1:3</td>
</tr>
</tbody>
</table>

NOTE: Values represent mean ± standard error. CI = 1, < 1, and > 1 indicates additivity, synergy, and antagonism, respectively. Abbreviations: IC$_{50}$, half maximal inhibitory concentration (for drug combinations, this represents total drug concentration); CI, combination index; F$_{aX}$, X% maximal fractional affect.

Table 1. Drug combination effects: combination index analysis of paclitaxel, rapamycin, and 17-AAG ($N = 4–5$ per condition)
Histologic assessment of normal organs (kidney, heart, liver, and lungs) was accomplished in parallel. No treatment led to acute renal or cardiac toxicities evident on standard hematoxylin and eosin evaluation (Supplemental Fig. S1). In the micelle alone group, a single mouse showed mild hepatic centrilobular chronic inflammation. Similarly, a single mouse in the Triolimus treated group showed mild hepatic centrilobular chronic inflammation. No other signs of hepatic toxicity were evident in the remaining 16 animals. No drug-related pulmonary toxicity was evident. However, in 5 animals, small tumor deposits were identified in lungs. There was no obvious, treatment group dependence to the presence of lung tumor deposits with lesions evident in 1, 2, and 2 of 6 animals in the micelle alone, paclitaxel-loaded micelle, and Triolimus-treated groups, respectively.

Triolimus-induced tumor growth delay is a consequence of both increased tumor cell apoptosis and reduced tumor cell proliferation

As shown in Fig. 4A, Triolimus reduced tumor cell proliferation, assessed by Ki-67 staining, by nearly 80% compared with control treated animals. This compared with slightly more than a 50% reduction in proliferation induced by paclitaxel-containing micelles. Similar results were obtained when the percent Ki-67-positive cells was quantified [unloaded micelles 10.2 ± 0.8%; paclitaxel-loaded micelles 5.0 ± 0.5%; Triolimus 2.3 ± 0.1% (ANOVA P < 0.0001, all pairwise comparisons P < 0.01 by Tukey’s HSD test)]. In addition to the antiproliferative effects, Triolimus more than quadrupled the number of apoptotic cells (Fig. 4B) whereas paclitaxel-containing micelles approximately doubled the rate of apoptosis in tumor cells. Again, similar results were obtained when the percent cleaved caspase-3-positive cells were quantified [unloaded micelles 1.2 ± 0.1%; paclitaxel-loaded micelles 3.1 ± 0.1%; Triolimus 6.1 ± 0.4% (ANOVA P < 0.0001, all pairwise comparisons P < 0.01 by Tukey’s HSD test)].

Discussion

This study examines the efficacy and safety of Triolimus, a novel systemic antineoplastic composed of micellized paclitaxel, rapamycin, and 17-AAG, in tumor models. Using 2 widely used, poorly differentiated, aggressive...
adenocarcinomas, A549 lung cancer, and MDA-MB-231 breast cancer, Triolimus was subjected to evaluation in vitro and in vivo. Triolimus components exerted variable independent cytotoxic effects in both cell lines. As previously reported, paclitaxel displayed potent cytotoxic effects in both cell lines (14–16). Also consistent with prior reports, A549 cells proved relatively sensitive to both 17-AAG and mTOR inhibition whereas MDA-MB-231 cells were directly compared; #, \( P < 0.05 \) (Student’s t test). Inset displays individual A549 tumor volumes in Triolimus-treated mice.

Mechanisms of synergistic cytotoxicity were explored in both cell lines. In A549 cells, no single drug effectively blocked activation of both the PI3K/Akt/mTOR and the Ras/Raf/MAPK pathways. The mTOR target, p70S6K, was phosphorylated in A549 cells that were untreated or treated with paclitaxel or 17-AAG monotherapy. Similarly, ERK 1/2 was phosphorylated in untreated A549 cells as well as those treated with single agent rapamycin and 17-AAG. Drug combinations that prevented both p70S6K and ERK 1/2 phosphorylation proved synergistic. Of the drug combinations tested, only paclitaxel plus 17-AAG proved antagonistic in A549 cells and this regimen was the only combination tested that failed to block phosphorylation of p70S6K. Compensatory Akt phosphorylation was observed with rapamycin monotherapy as previously reported (19,20). Consistent with the rationale behind Triolimus design, as well as the synergistic cytotoxicity of 17-AAG and rapamycin, compensatory Akt phosphorylation driven by rapamycin was completely inhibited by the inclusion of 17-AAG.

Similar mechanisms of cytotoxic synergy in MDA-MB-231 cells are suggested. However, effects appear less straightforward. As with A549 cells, combinations that blocked both p70S6K and ERK 1/2 phosphorylation proved synergistic. However, the only drug combination that failed to inhibit activation of both of these key downstream targets, paclitaxel plus 17-AAG, also showed mild cytotoxic synergy throughout the fractional effect range (CI = 0.6–0.7). Nonetheless, as in the case of A549 cells, this drug combination was the least synergistic of any combination tested. There are multiple potential explanations for the observed cell line differences including variations in basal activation of the PI3K/Akt/mTOR and the Ras/Raf/MAPK pathways, stark differences in cell sensitivity to monotherapies and alternative, unexplored, drug effects. Given the multitude of Hsp90 client proteins and the observation that the expression and activation of prosen drug targets differed only modestly between 3-drug treated and untreated MDA-MB-231 cells, it seems highly likely that unexplored drug effects are contributing to the synergistic activity observed.

Triolimus proved significantly more effective than paclitaxel-containing micelles in both the heterotopic A549 flank tumor model and the orthotopic MDA-MB-231 tumor model. In the latter, a single course of three Triolimus infusions resulted in tumor cures. Triolimus potency is attributable to marked increases in tumor cell apoptosis and concomitant reductions in tumor cell proliferation. These results are consistent with extensive preclinical data. Both 17-AAG and rapamycin have been shown to sensitize multiple cancer cell lines to paclitaxel-induced apoptosis (5, 21–24). Furthermore, all 3 agents have been implicated in cell-cycle arrest and reductions in cell proliferation (25–27).

In vitro results suggest the striking activity of Triolimus in vivo may be a consequence of synergistic cytotoxicity. However, given the addition of both rapamycin (30 mg/kg) and 17-AAG (60 mg/kg) to paclitaxel (60 mg/kg), treatment intensification also likely contributes to the enhanced tumor growth delays observed with Triolimus. This treatment intensification is made possible through the use of the micellar delivery system. In the absence of PEG-PLA formulation, the maximum tolerated dose (MTD) of paclitaxel in mice is approximately
The use of PEG-PLA micelles for multidrug delivery represents an attractive opportunity to leverage a novel drug delivery system for dose-escalated molecular multitargeting. A key clinical question when evaluating any dose-intensified regimen is whether improvements in efficacy are counterbalanced by increased toxicity thereby limiting the therapeutic ratio. Triolimus resulted in no animal toxicity and liver function testing were essentially unremarkable compared with both paclitaxel-containing micelles and vehicle control. Alkaline phosphatase was modestly elevated with Triolimus treatment, however, total bilirubin remained undetectable, transaminases were unchanged (to lower) and hepatic synthetic function (albumin, total protein) was unmodified. Mild hyperlipidemia, including mild hypercholesterolemia, was unmodified. Mild hyperglycemia was observed with Triolimus treatment. Glucose levels were significantly increased by Triolimus compared with both paclitaxel-containing micelles and vehicle control (Table 2).

Table 2. Toxicity of paclitaxel-containing micelles and Triolimus (N = 6 per group)

<table>
<thead>
<tr>
<th></th>
<th>Micelle alone (mean ± SE)</th>
<th>Paclitaxel-containing micelle (mean ± SE)</th>
<th>Triolimus (mean ± SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na, mmol/L</td>
<td>144 ± 1</td>
<td>146 ± 1</td>
<td>148 ± 1</td>
</tr>
<tr>
<td>K, mmol/L</td>
<td>5.1 ± 0.5</td>
<td>4.1 ± 0.2</td>
<td>3.8 ± 0.2</td>
</tr>
<tr>
<td>Cl, mmol/L</td>
<td>112 ± 1</td>
<td>112 ± 1</td>
<td>116 ± 1</td>
</tr>
<tr>
<td>CO₂, mmol/L</td>
<td>22 ± 1</td>
<td>24 ± 1</td>
<td>22 ± 1</td>
</tr>
<tr>
<td>Anion Gap, mmol/L</td>
<td>15 ± 1</td>
<td>14 ± 1</td>
<td>14 ± 1</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>183 ± 18</td>
<td>202 ± 10</td>
<td>259 ± 72</td>
</tr>
<tr>
<td>BUN, mg/dL</td>
<td>22 ± 1</td>
<td>23 ± 1</td>
<td>18 ± 1</td>
</tr>
<tr>
<td>Cr, mg/dL</td>
<td>0.2 ± 0.05</td>
<td>0.2 ± 0.02</td>
<td>0.2 ± 0.02</td>
</tr>
<tr>
<td>Ca, mg/dL</td>
<td>9.1 ± 0.1</td>
<td>9.0 ± 0.1</td>
<td>9.2 ± 0.1</td>
</tr>
<tr>
<td>Phos, mg/dL</td>
<td>6.1 ± 0.3</td>
<td>5.4 ± 0.2</td>
<td>5.9 ± 0.2</td>
</tr>
<tr>
<td>Mg (mg/dL)</td>
<td>2.1 ± 0.1</td>
<td>2.0 ± 0.1</td>
<td>2.0 ± 0.1</td>
</tr>
<tr>
<td>TPot, g/dL</td>
<td>4.7 ± 0.2</td>
<td>4.7 ± 0.1</td>
<td>4.7 ± 0.1</td>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td>1.9 ± 0.1</td>
<td>2.0 ± 0.1</td>
<td>2.1 ± 0.1</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>125 ± 25</td>
<td>66 ± 4</td>
<td>60 ± 4</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>46 ± 8</td>
<td>32 ± 4</td>
<td>35 ± 3</td>
</tr>
<tr>
<td>Alk Phos, U/L</td>
<td>68 ± 5</td>
<td>86 ± 9</td>
<td>99 ± 5a</td>
</tr>
<tr>
<td>tBili, mg/dL</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Total Chol, mg/dL</td>
<td>88 ± 5</td>
<td>107 ± 6</td>
<td>134 ± 7a</td>
</tr>
<tr>
<td>Trig, mg/dL</td>
<td>82 ± 9</td>
<td>142 ± 30</td>
<td>140 ± 29</td>
</tr>
<tr>
<td>HCT, %</td>
<td>42 ± 1b</td>
<td>36 ± 1a</td>
<td>39 ± 1</td>
</tr>
<tr>
<td>Hgb, g/dL</td>
<td>13.8 ± 0.2a</td>
<td>11.5 ± 0.3a</td>
<td>12.6 ± 0.2</td>
</tr>
<tr>
<td>WBC, 10⁸/mm³</td>
<td>4.8 ± 1.3</td>
<td>1.8 ± 0.4</td>
<td>1.5 ± 0.4</td>
</tr>
<tr>
<td>Platelets, 10⁶/mm³</td>
<td>1,060 ± 186</td>
<td>1,385 ± 183</td>
<td>1,128 ± 86</td>
</tr>
</tbody>
</table>

aSignificantly different from micelle alone group (P < 0.0022).
bSignificantly different from paclitaxel-containing micelle group (P < 0.0022). Statistical significance of P < 0.0022 accounts for multiple comparison correction (Bonferroni correction for 23 comparisons). Uncorrected P values for all comparisons are available in Supplementary Table S1.

20 mg/kg in standard polyethoxylated castor oil (i.e. Cremophor EL, Taxol; 28). Triolimus permits simultaneous delivery of paclitaxel at three times this MTD as well as 17-AAG at approximately 75% of MTD and high doses of rapamycin (29–30). Each agent, when delivered parenterally, must be formulated with a solubilizer that can have independent toxicities. Paclitaxel is routinely parenterally, must be formulated with a solubilizer that...
statistically significant hypercholesterolemia, and hyperglycemia were evident in Triolimus treated animals. As hyperlipidemia and hyperglycemia are dose-dependent side effects of rapamycin and 17-AAG, respectively, these biochemical changes provide circumstantial evidence for the activity of these pharmacophores following Triolimus infusion and may provide useful markers for dosing strategies during clinical development (36, 37).

Myelosuppression is a dose-limiting toxicity of taxanes and paclitaxel-containing micelles did result in hematologic toxicity including mild anemia and reductions in white blood cell counts. Triolimus did not enhance myelosuppression compared with paclitaxel-containing micelles. In fact, no anemia or thrombocytopenia was evident in Triolimus treated animals. Reductions in white blood cell counts were comparable in both paclitaxel and Triolimus treated groups but did not achieve statistical significance in part because of considerable variability in control animals. The absence of statistically significant neutropenia must be caveated by the recognition that host animals are immunosuppressed at baseline and ongoing studies are defining the hematologic toxicity of Triolimus in immunocompetent animals. More globally, potential disconnects between murine tolerability and human safety as well as extensive regulatory requirements necessitate further safety testing before advancing to human studies. Nonetheless, these data suggest Triolimus widens the therapeutic ratio compared with paclitaxel monotherapy.

Triolimus represents a novel systemic therapy that permits simultaneous, dose-escalated targeting of the microtubule apparatus, mTOR and Hsp90. Triolimus displays synergistic cytotoxicity in vitro, effectively inhibits the PI3K/Akt/mTOR and Ras/Raf/MAPK pathways, has impressive in vivo antitumor activity and is associated with modest toxicity. Results of these studies provide a strong foundation for further preclinical and clinical development of Triolimus and provide a proof of concept for the use of polymeric micelle nanocarriers in the rational design of combination cancer therapy.

Moreover, Triolimus reflects an emerging, and key, concept in combinatorial, cancer medicine. The accelerating pace of molecular target (and drug) identification, coupled with a growing understanding of molecular resistance mechanisms, continuously provides evidence to support novel drug combinations. In parallel, the development of a wide array of nanomaterials for clinical use offers new opportunities to deliver drug combinations (38–40). Insightful matching of pharmacophores with drug delivery vehicle will be essential in therapeutic design. For example, the PEG-PLA micellar construct of...
Triolimus is well-suited for efficient solubilization of the 3 synergetic, hydrophobic agents used here (12,13,41). However, several rational drug combinations can be envisioned that do not share the physicochemical properties of paclitaxel, rapamycin, and I7-AAG. In such cases, alternative drug-delivery vehicles may prove superior to micelles. For example, Ahmed and colleagues endeavored to develop a therapeutic capable of simultaneously delivering the hydrophobic agent paclitaxel and the hydrophilic cytotoxic doxorubicin. In this case, biodegradable polymersomes were effectively exploited to solubilize paclitaxel in the thick polymersome hydrophobic membrane while encapsulating doxorubicin in the aqueous vesicular lumen (42, 43). This illustrates the critical need for close collaboration of oncologists, biologists, and pharmacist scientists in maximizing clinical progress (44).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


Authors’ Contributions

Conception and design: J.R. Hasenstein, G. Kwon, K.R. Kozak
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.R. Hasenstein, H.-C. Shin, K. Kasmerchak, D. Buehler, K.R. Kozak
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.R. Hasenstein, H.-C. Shin, K. Kasmerchak, D. Buehler, K.R. Kozak
Writing, review, and/or revision of the manuscript: J.R. Hasenstein, H.-C. Shin, K. Kasmerchak, D. Buehler, G. Kwon, K.R. Kozak
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.R. Hasenstein
Study supervision: K.R. Kozak

Grant Support

Supported in part by NIH Grants 1UL1RR025011 (K. R. Kozak) and R21CA161537 (G. S. Kwon)

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 6, 2011; revised June 19, 2012; accepted July 23, 2012; published OnlineFirst August 14, 2012.
44. Author websites: Kozak Laboratory: http://www.humonc.wisc.edu/index.php/Kozak_Lab and Kwon Laboratory: http://apps.pharmacy.wisc.edu/sopdir/39
Molecular Cancer Therapeutics

Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG

Jason R. Hasenstein, Ho-Chul Shin, Kelsey Kasmerchak, et al.

Mol Cancer Ther  Published OnlineFirst August 14, 2012.

Updated version: Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-11-0987

Supplementary Material: Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2012/08/14/1535-7163.MCT-11-0987.DC1

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.